Option Care Health, Inc. OPCH
Option Care Health, Inc. (“Option Care Health”, “we”, “us”, “our”, or the “Company”) is the largest independent provider of home and alternate site infusion services through its national network of 196 locations in 43 states. 10-K, Item 1
- Employees
- 2,700
- Headquarters
- Bannockburn, IL
- Next results
- around Jan 11, 2027
Where each dollar of revenue went, FY2025
Revenue of $5.6B through the costs to a net profit of $207.6M · income statement of the 10-K
OPCH among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
9 new risk paragraphs. 10-K filed Feb 24, 2026 against Feb 26, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
0facts worth reading about all 11 checks found nothing to note
-
Receivables +15.6% ($409.7M to $473.6M) vs revenue +13.0% ($5.0B to $5.6B), +2.5 pts apart
-
Cash from operations $258.4M vs net income $207.6M (FY ending Dec 31, 2025)
-
Inventory +21.4% ($388.1M to $471.1M) vs revenue +13.0% ($5.0B to $5.6B), +8.4 pts apart
8 more checks with nothing to note
-
Same auditor in both 10-Ks: KPMG LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Sufficiency of audit evidence over the evaluation of transaction price adjustments
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
9 paragraphs in Risk Factors that were not in the 10-K filed Feb 26, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
Increasing competition from established and vertically integrated healthcare providers, coupled with industry consolidation and cost pressures, may limit our ability to grow revenue, maintain pricing, secure favorable contracts, and access critical pharmaceutical products.
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
Contracts and fee schedules for prescription drug reimbursement, including our contracts with commercial payers, PBMs, and Medicaid programs, generally use certain published benchmarks to establish pricing. These benchmarks include Average Wholesale Price (“AWP”), Wholesale Acquisition price (“WAC”), Average Selling Price (“ASP”), among…
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
Our business could be adversely affected if we fail to effectively adopt and integrate evolving technologies such as artificial intelligence (“AI”), attract and retain necessary technical talent, or adapt to competitive, technological, or structural changes in the healthcare products and services industry, any of which could impair our…
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
Ongoing reimbursement rate reductions, pricing pressures from Third-Party Payers and managed care payers, and increasing payer consolidation could significantly impact revenue, reduce profitability, and concentrate financial dependence on a few large payers.
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $3.9B | $4.3B | $5.0B | $5.6B |
| Net income | $150.6M | $267.1M | $211.8M | $207.6M |
| Operating cash flow | $267.5M | $371.3M | $323.4M | $258.4M |
| Free cash flow | $232.2M | $329.4M | $287.8M | $217.1M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$5.6B ▲ 13.0% in FY2025$207.6M ▼ 2.0% in FY2025$217.1M ▼ 24.5% in FY2025
Recent filings
3 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 10, 2026Robert C Pate (Director) gave notice of a planned sale of 6,492 shares worth about $208K Form 144, approximate sale date Nov 10, 2026
-
8-KNov 4, 2026Quarterly results 8-K item 2.02
-
10-QNov 4, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
Option Care Health, Inc., Bannockburn, IL · from the 10-K filed Feb 24, 2026
Option Care Health, Inc. (“Option Care Health”, “we”, “us”, “our”, or the “Company”) is the largest independent provider of home and alternate site infusion services through its national network of 196 locations in 43 states. Option Care Health draws on over 40 years of clinical care experience to offer patient-centered, cost-effective infusion therapy. Option Care Health’s infusion services include the clinical management of infusion therapy, nursing support and care coordination.
- Headquarters
- Bannockburn, IL
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 4, 2026
- Incorporated in
- DE
Employees, at the top of the page: "The Company also provides nursing services to support the above therapies, comprised of its nursing team of approximately 2,700 employees, and through its network of sub-contracted nursing agencies" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 24, 2026 (open at SEC), compared with the 10-K filed Feb 26, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/OPCH/export.csv") into a cell.